| Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia SL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, ... New England Journal of Medicine 378 (5), 439-448, 2018 | 5319 | 2018 |
| Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, ... New England Journal of Medicine 378 (8), 731-739, 2018 | 2745 | 2018 |
| Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, ... The Lancet Oncology 21 (4), 531-540, 2020 | 927 | 2020 |
| Comprehensive analysis of hypermutation in human cancer BB Campbell, N Light, D Fabrizio, M Zatzman, F Fuligni, R de Borja, ... Cell 171 (5), 1042-1056. e10, 2017 | 769 | 2017 |
| Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study TW Laetsch, SG DuBois, L Mascarenhas, B Turpin, N Federman, ... The Lancet Oncology 19 (5), 705-714, 2018 | 555 | 2018 |
| Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma MC Pasquini, ZH Hu, K Curran, T Laetsch, F Locke, R Rouce, ... Blood advances 4 (21), 5414-5424, 2020 | 393 | 2020 |
| Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of … B Geoerger, HJ Kang, M Yalon-Oren, LV Marshall, C Vezina, A Pappo, ... The Lancet Oncology 21 (1), 121-133, 2020 | 297 | 2020 |
| Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma VA Pullarkat, NJ Lacayo, E Jabbour, JE Rubnitz, A Bajel, TW Laetsch, ... Cancer discovery 11 (6), 1440-1453, 2021 | 232 | 2021 |
| Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia KT Mueller, E Waldron, SA Grupp, JE Levine, TW Laetsch, MA Pulsipher, ... Clinical cancer research 24 (24), 6175-6184, 2018 | 232 | 2018 |
| Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial TW Laetsch, SL Maude, S Rives, H Hiramatsu, H Bittencourt, P Bader, ... Journal of Clinical Oncology 41 (9), 1664-1669, 2023 | 218 | 2023 |
| Pan-Trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors ER Rudzinski, CM Lockwood, BA Stohr, SO Vargas, R Sheridan, JO Black, ... The American journal of surgical pathology 42 (7), 927-935, 2018 | 204 | 2018 |
| Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL RM Myers, A Taraseviciute, SM Steinberg, AJ Lamble, J Sheppard, ... Journal of Clinical Oncology 40 (9), 932-944, 2022 | 177 | 2022 |
| Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor … LM Schultz, C Baggott, S Prabhu, HL Pacenta, CL Phillips, J Rossoff, ... Journal of Clinical Oncology 40 (9), 945-955, 2022 | 166 | 2022 |
| Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia MA Pulsipher, X Han, SL Maude, TW Laetsch, M Qayed, S Rives, ... Blood Cancer Discovery 3 (1), 66-81, 2022 | 143 | 2022 |
| The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas SG DuBois, TW Laetsch, N Federman, BK Turpin, CM Albert, ... Cancer 124 (21), 4241-4247, 2018 | 142 | 2018 |
| Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study W Sun, J Malvar, R Sposto, A Verma, JJ Wilkes, R Dennis, K Heym, ... Leukemia 32 (11), 2316-2325, 2018 | 131 | 2018 |
| Expanding the spectrum of pediatric NTRK-rearranged mesenchymal tumors JL Davis, CM Lockwood, B Stohr, C Boecking, A Al-Ibraheemi, SG DuBois, ... The American journal of surgical pathology 43 (4), 435-445, 2019 | 126 | 2019 |
| Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors F Doz, CM Van Tilburg, B Geoerger, M Højgaard, I Øra, V Boni, M Capra, ... Neuro-oncology 24 (6), 997-1007, 2022 | 124 | 2022 |
| Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukemia SA Grupp, SL Maude, S Rives, A Baruchel, MW Boyer, H Bittencourt, ... Blood 132, 895, 2018 | 122 | 2018 |
| Tisagenlecleucel model‐based cellular kinetic analysis of chimeric antigen receptor–T cells AM Stein, SA Grupp, JE Levine, TW Laetsch, MA Pulsipher, MW Boyer, ... CPT: pharmacometrics & systems pharmacology 8 (5), 285-295, 2019 | 119 | 2019 |
